Cargando…
Correction to: The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689645/ https://www.ncbi.nlm.nih.gov/pubmed/33243191 http://dx.doi.org/10.1186/s12879-020-05628-w |
| _version_ | 1783613897044918272 |
|---|---|
| author | Gharebaghi, Naser Nejadrahim, Rahim Mousavi, Seyed Jalil Sadat-Ebrahimi, Seyyed-Reza Hajizadeh, Reza |
| author_facet | Gharebaghi, Naser Nejadrahim, Rahim Mousavi, Seyed Jalil Sadat-Ebrahimi, Seyyed-Reza Hajizadeh, Reza |
| author_sort | Gharebaghi, Naser |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7689645 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-76896452020-11-27 Correction to: The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial Gharebaghi, Naser Nejadrahim, Rahim Mousavi, Seyed Jalil Sadat-Ebrahimi, Seyyed-Reza Hajizadeh, Reza BMC Infect Dis Correction BioMed Central 2020-11-26 /pmc/articles/PMC7689645/ /pubmed/33243191 http://dx.doi.org/10.1186/s12879-020-05628-w Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
| spellingShingle | Correction Gharebaghi, Naser Nejadrahim, Rahim Mousavi, Seyed Jalil Sadat-Ebrahimi, Seyyed-Reza Hajizadeh, Reza Correction to: The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial |
| title | Correction to: The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial |
| title_full | Correction to: The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial |
| title_fullStr | Correction to: The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial |
| title_full_unstemmed | Correction to: The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial |
| title_short | Correction to: The use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial |
| title_sort | correction to: the use of intravenous immunoglobulin gamma for the treatment of severe coronavirus disease 2019: a randomized placebo-controlled double-blind clinical trial |
| topic | Correction |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7689645/ https://www.ncbi.nlm.nih.gov/pubmed/33243191 http://dx.doi.org/10.1186/s12879-020-05628-w |
| work_keys_str_mv | AT gharebaghinaser correctiontotheuseofintravenousimmunoglobulingammaforthetreatmentofseverecoronavirusdisease2019arandomizedplacebocontrolleddoubleblindclinicaltrial AT nejadrahimrahim correctiontotheuseofintravenousimmunoglobulingammaforthetreatmentofseverecoronavirusdisease2019arandomizedplacebocontrolleddoubleblindclinicaltrial AT mousaviseyedjalil correctiontotheuseofintravenousimmunoglobulingammaforthetreatmentofseverecoronavirusdisease2019arandomizedplacebocontrolleddoubleblindclinicaltrial AT sadatebrahimiseyyedreza correctiontotheuseofintravenousimmunoglobulingammaforthetreatmentofseverecoronavirusdisease2019arandomizedplacebocontrolleddoubleblindclinicaltrial AT hajizadehreza correctiontotheuseofintravenousimmunoglobulingammaforthetreatmentofseverecoronavirusdisease2019arandomizedplacebocontrolleddoubleblindclinicaltrial |